Evidence map›Paper›PMID 39100671›Full record

ReviewFrontiers in immunology2024

Advances and clinical challenges of mesenchymal stem cell therapy.

Ruiyan Mei, Zhuo Wan, Cheng Yang, Xiangjing Shen, Ronglin Wang, Haihua Zhang, Rui Yang, Junqiang Li, Yang Song, Haichuan Su

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Stem Cells in Aging and Anti-Aging.Stem cell reviews and reports · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruiyan Mei *Department of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Zhuo Wan *Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Cheng Yang *Department of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Xiangjing ShenDepartment of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Ronglin WangDepartment of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Haihua ZhangDepartment of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Rui YangDepartment of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Junqiang LiDepartment of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Yang SongDepartment of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Haichuan SuDepartment of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, cell therapy has provided desirable properties for promising new drugs. Mesenchymal stem cells are promising candidates for developing genetic engineering and drug delivery strategies due to their inherent properties, including immune regulation, homing ability and tumor tropism. The therapeutic potential of mesenchymal stem cells is being investigated for cancer therapy, inflammatory and fibrotic diseases, among others. Mesenchymal stem cells are attractive cellular carriers for synthetic nanoparticles for drug delivery due to their inherent homing ability. In this review, we comprehensively discuss the various genetic and non-genetic strategies of mesenchymal stem cells and their derivatives in drug delivery, tumor therapy, immune regulation, tissue regeneration and other fields. In addition, we discuss the current limitations of stem cell therapy and the challenges in clinical translation, aiming to identify important development areas and potential future directions.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsDrug Delivery SystemsHumansNeoplasmscell homingclinical usedrug deliverymesenchymal stem cellnanoparticles

Identifiers

PMID39100671
PMCPMC11294097

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.